About This Event

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Martin Babler, Alumis’ President, CEO & Chairman of the Board, rings the Opening Bell.